Intranasal Oxytocin for Obesity.

Plessow F, Kerem L, Wronski ML, Asanza E, O'Donoghue ML, Stanford FC, Eddy KT, Holmes TM, Misra M, Thomas JJ, Galbiati F, Muhammed M and 13 more

Show all authors

Sella AC, Hauser K, Smith SE, Holman K, Gydus J, Aulinas A, Vangel M, Healy B, Kheterpal A, Torriani M, Holsen LM, Bredella MA, Lawson EA

NEJM evidence23 Apr 2024Cited by 22 (Europe PMC)

PMID38815173PMCIDPMC11427243DOI10.1056/evidoa2300349PepBankPUB-38815173

Source link PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with obesity, intranasal oxytocin did not change body weight at week 8 compared with placebo.
In plain wordsIn adults with obesity, oxytocin nasal spray did not change body weight more than placebo.
Peptide
Oxytocin
Outcome
No significant changeBody weight change from baseline to week 8
Study
n = 61
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
24 IU four times daily · intranasal · 8 weeksAs given in this study (human).
Measurements
Body weight change
0.2 kg
oxytocin
Body weight change
0.26 kg
placebo
Source sentences
Summary
There was no difference in body weight change from baseline to week 8 between oxytocin and placebo groups (0.20 vs. 0.26 kg; P=0.934).
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomized, double-blind, placebo-controlled trial, we randomly assigned adults with obesity 1:1 (stratified by sex and obesity class) to receive intranasal oxytocin (24 IU) or placebo four times daily for 8 weeks.
Summary · context
Sixty-one participants (54% women; mean age ± standard deviation, 33.6 ± 6.2 years; body-mass index [the weight in kilograms divided by the square of the height in meters], 36.9 ± 4.9) were randomly assigned.
Report a problemFND-3881517301
02HumanRandomized controlled trialEfficacy outcome
In adults with obesity, oxytocin did not change total fat mass versus placebo.
In plain wordsIn adults with obesity, oxytocin did not change total body fat compared with placebo.
Peptide
Oxytocin
Outcome
No significant changeTotal fat mass change
Study
n = 61
Comparator
Placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
24 IU four times daily · intranasal · 8 weeksAs given in this study (human).
Measurements
Difference in total fat
196 g
oxytocin vs placebo
Source sentences
Summary
Oxytocin (vs. placebo) was not associated with beneficial effects on body composition or resting energy expenditure from
3 context sentences(design, population, supporting numbers)
Summary · context
total fat: difference [95% confidence interval], 196.0 g [-1036 to 1428]
Summary · context
In this randomized, double-blind, placebo-controlled trial, we randomly assigned adults with obesity 1:1 (stratified by sex and obesity class) to receive intranasal oxytocin (24 IU) or placebo four times daily for 8 weeks.
Summary · context
Sixty-one participants (54% women; mean age ± standard deviation, 33.6 ± 6.2 years; body-mass index [the weight in kilograms divided by the square of the height in meters], 36.9 ± 4.9) were randomly assigned.
Report a problemFND-3881517302
03HumanRandomized controlled trialEfficacy outcome
In adults with obesity, oxytocin did not change abdominal visceral fat versus placebo.
In plain wordsIn adults with obesity, oxytocin did not change belly fat compared with placebo.
Peptide
Oxytocin
Outcome
No significant changeVisceral adipose tissue change
Study
n = 61
Comparator
Placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
24 IU four times daily · intranasal · 8 weeksAs given in this study (human).
Measurements
Difference in visceral fat
3.1 cm2
oxytocin vs placebo
Source sentences
Summary
Oxytocin (vs. placebo) was not associated with beneficial effects on body composition or resting energy expenditure from
3 context sentences(design, population, supporting numbers)
Summary · context
visceral fat: 3.1 cm² [-11.0 to 17.2]
Summary · context
In this randomized, double-blind, placebo-controlled trial, we randomly assigned adults with obesity 1:1 (stratified by sex and obesity class) to receive intranasal oxytocin (24 IU) or placebo four times daily for 8 weeks.
Summary · context
Sixty-one participants (54% women; mean age ± standard deviation, 33.6 ± 6.2 years; body-mass index [the weight in kilograms divided by the square of the height in meters], 36.9 ± 4.9) were randomly assigned.
Report a problemFND-3881517303
04HumanRandomized controlled trialEfficacy outcome
In adults with obesity, oxytocin did not change liver fat fraction versus placebo.
In plain wordsIn adults with obesity, oxytocin did not change liver fat compared with placebo.
Peptide
Oxytocin
Outcome
No significant changeLiver fat fraction change
Study
n = 61
Comparator
Placebo
Analysis
Secondary
Outcome group
Liver fat and liver function · Liver
Studied dose
24 IU four times daily · intranasal · 8 weeksAs given in this study (human).
Measurements
Difference in liver fat fraction
−0.01 proportion
oxytocin vs placebo
Source sentences
Summary
Oxytocin (vs. placebo) was not associated with beneficial effects on body composition or resting energy expenditure from
3 context sentences(design, population, supporting numbers)
Summary · context
liver fat: -0.01 [-0.03 to 0.01]
Summary · context
In this randomized, double-blind, placebo-controlled trial, we randomly assigned adults with obesity 1:1 (stratified by sex and obesity class) to receive intranasal oxytocin (24 IU) or placebo four times daily for 8 weeks.
Summary · context
Sixty-one participants (54% women; mean age ± standard deviation, 33.6 ± 6.2 years; body-mass index [the weight in kilograms divided by the square of the height in meters], 36.9 ± 4.9) were randomly assigned.
Report a problemFND-3881517304
05HumanRandomized controlled trialEfficacy outcome
In adults with obesity, oxytocin did not change resting energy expenditure versus placebo.
In plain wordsIn adults with obesity, oxytocin did not change resting energy use compared with placebo.
Peptide
Oxytocin
Outcome
No significant changeResting energy expenditure change
Study
n = 61
Comparator
Placebo
Analysis
Secondary
Outcome group
Energy expenditure and thermogenesis · Metabolic and weight
Studied dose
24 IU four times daily · intranasal · 8 weeksAs given in this study (human).
Measurements
Difference in resting energy expenditure
−64 kcal/day
oxytocin vs placebo
Source sentences
Summary
Oxytocin (vs. placebo) was not associated with beneficial effects on body composition or resting energy expenditure from
3 context sentences(design, population, supporting numbers)
Summary · context
resting energy expenditure: -64.0 kcal/day [-129.3 to 1.4]
Summary · context
In this randomized, double-blind, placebo-controlled trial, we randomly assigned adults with obesity 1:1 (stratified by sex and obesity class) to receive intranasal oxytocin (24 IU) or placebo four times daily for 8 weeks.
Summary · context
Sixty-one participants (54% women; mean age ± standard deviation, 33.6 ± 6.2 years; body-mass index [the weight in kilograms divided by the square of the height in meters], 36.9 ± 4.9) were randomly assigned.
Report a problemFND-3881517305
06HumanRandomized controlled trialEfficacy outcome
In adults with obesity, oxytocin was associated with reduced caloric intake at the test meal compared with placebo.
In plain wordsIn adults with obesity, oxytocin was linked to eating fewer calories at a test meal than placebo.
Peptide
Oxytocin
Outcome
DecreaseCaloric intake at test meal
Study
n = 61
Comparator
Placebo
Analysis
Secondary
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
24 IU four times daily · intranasal · 8 weeksAs given in this study (human).
Measurements
Difference in caloric intake
−152 kcal
oxytocin vs placebo
Source sentences
Summary
Oxytocin compared with placebo was associated with reduced caloric intake at the test meal (-31.4 vs. 120.6 kcal; difference [95% confidence interval], -152.0 kcal [-302.3 to -1.7]).
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomized, double-blind, placebo-controlled trial, we randomly assigned adults with obesity 1:1 (stratified by sex and obesity class) to receive intranasal oxytocin (24 IU) or placebo four times daily for 8 weeks.
Summary · context
Sixty-one participants (54% women; mean age ± standard deviation, 33.6 ± 6.2 years; body-mass index [the weight in kilograms divided by the square of the height in meters], 36.9 ± 4.9) were randomly assigned.
Report a problemFND-3881517306
07HumanRandomized controlled trialSafety outcome
In adults with obesity, there were no serious adverse events with oxytocin or placebo.
In plain wordsIn adults with obesity, no serious side effects occurred in the trial.
Peptide
Oxytocin
Outcome
No significant changeSerious adverse events
Study
n = 61
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
24 IU four times daily · intranasal · 8 weeksAs given in this study (human).
Source sentences
Summary
There were no serious adverse events.
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomized, double-blind, placebo-controlled trial, we randomly assigned adults with obesity 1:1 (stratified by sex and obesity class) to receive intranasal oxytocin (24 IU) or placebo four times daily for 8 weeks.
Summary · context
Sixty-one participants (54% women; mean age ± standard deviation, 33.6 ± 6.2 years; body-mass index [the weight in kilograms divided by the square of the height in meters], 36.9 ± 4.9) were randomly assigned.
Report a problemFND-3881517307
08HumanRandomized controlled trialSafety outcome
In adults with obesity, incidence and severity of adverse events did not differ between oxytocin and placebo.
In plain wordsIn adults with obesity, side effects were no more common or severe with oxytocin than with placebo.
Peptide
Oxytocin
Outcome
No significant changeIncidence and severity of adverse events
Study
n = 61
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
24 IU four times daily · intranasal · 8 weeksAs given in this study (human).
Source sentences
Summary
Incidence and severity of adverse events did not differ between groups.
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomized, double-blind, placebo-controlled trial, we randomly assigned adults with obesity 1:1 (stratified by sex and obesity class) to receive intranasal oxytocin (24 IU) or placebo four times daily for 8 weeks.
Summary · context
Sixty-one participants (54% women; mean age ± standard deviation, 33.6 ± 6.2 years; body-mass index [the weight in kilograms divided by the square of the height in meters], 36.9 ± 4.9) were randomly assigned.
Report a problemFND-3881517308

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT03043053

The Effects of Oxytocin in Obese Adults

Massachusetts General Hospitaln = 611 Jul 2017 to 7 Jul 2022

Obesity

Trial page ClinicalTrials.govUpdated 7 Feb 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.